Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 1996

View Archived Issues

Menarini and Lilly sign comarketing agreement

Actiq to undergo phase III clinical trials

Lidocaine nasal drops shown effective for fast migraine pain relief

5-HT1 agonists described by Merck & Co.

Isotretinoin effective against acne

Johnson & Johnson files patent infringement complaint against Penederm

Kaken submits NDA for Fiblast in Japan

Hemaseel HMN phase I results announced

Celley issued patent for physiologic lipid mixture from Australian authorities

FK-506: A safe and effective atopic dermatitis treatment

Beta-Lactamase inhibitors for treatment of penicillin-resistant infections

Licensing agreement signed for rifaximin

Novel oxazolidinone antibacterial agents reported by Bayer

Antibacterial peptides from Sanwa Kagaku

Antiviral pyrimidine derivatives described by Nippon Shoji

Study of Epivir's effect on HIV survival and disease progression terminated

Emory University issued U.S. patent covering Epivir

Emory University files Epivir patent infringement action

BioChem Pharma to challenge Epivir patent

A-76202: Alpha-glucosidase/sucrase-isomaltase complex inhibitor from Sankyo

Immtech's r(m)CRP HIV treatment covered under U.S. patent

Cel-Sci now holds full rights to HGP-30

GalaGen's Sporidin G enters phase II/III

VX-478 covered under U.S. patent for HIV/AIDS

RD4-2025: Selective HIV-1 reverse transcriptase inhibitor in vitro

MK7634 described in world patent

Niacinamide development update

Japan Tobacco describes cell adhesion inhibitors

Palauolol: A novel antiinflammatory phospholipase A2 inhibitor

MGI Pharma issued Israeli marketing approval for Salagen line extension

Immunostimulant series described by Takeda

American Home Products claims rapamycin compounds

Peptech issued U.S. patent for GMDP as antiinflammatory agent

Peptech's PTL-78419 covered under U.S. and European patents

SangStat's Thymoglobulin nearing phase III trials completion

Sangstat initiates cyclosporine and azathioprine bioequivalence trials

Allotrap 2702 enters second phase II trials

Aryl-ureido anticancer agents reported by Universite Laval

RPR seeks approval of Campto in 13 European countries

Mylan to market generic Taxol in 3 countries

BEC2, ImClone Systems' therapeutic vaccine protected under U.S. patent

Water-soluble prodrug of pancratistatin synthesized by Arizona State University

Duphar reports Vitamin D compounds with multiple therapeutic activity

New formulation of salmon calcitonin undergoes U.S. phase I trial

Yamanouchi reports squalene synthase inhibitors

Alfa Wasserman reveals antioxidant hypolipidemic compounds

Amgen and Kirin sign NESP collaboration

FDA approves expanded date labelling for LeukoNet

Sanwa Kagaku reveals selectin inhibitors

BRACAone undergoes beta-site testing in U.S.

OncorMed to offer genetic testing for BRC2 mutations

Multiuse melatonergic 3-alkoxybenzylpiperidine derivatives from Bristol-Myers Squibb

ADIR describes compunds with high affinity for 5-HT2C and/or 5-HT3C receptors

5-HT1A agonist with alpha1-adrenoceptor-blocking properties from Byk Gulden

SIBIA and Cognetix sign conopeptide research collaboration

Genomic map development accord signed

University of Colorado's ribozyme technology protected by Japanese patent

Merck discontinues screening agreement with Martek

Collaboration on production/delivery system of microbial antigens announced

Guilford obtains exclusive rights to drug delivery technology

Sequana to acquire NemaPharm

European patent broadly protects Pharming's transgenic cattle generation technology

White Iris leukocyte differential analyzer cleared for U.S. market

Centocor named "Best Biotechnology Company"

Incyte acquires Genome Systems

Cambridge Biotech's Chapter 11 reorganization plan approved

Gelman Sciences and Memtec to merge

Apotex acquires Protein S.A. de C.V.

Resource Biometrics acquired by IBAH

Health-Mark Diagnostics is now wholly owned by TCPI

Teva's Copaxone progresses toward FDA approval

Dainippon's new compound superior to metoclopramide for digestive function improvement

NMDA antagonists claimed by E. Merck

Sandoz's Exelon shows positive results in phase III

NMPA and/or AMPA antagonists from Warner-Lambert

Neurex's SNX-111 progresses through clinical trials

Hoechst Marion Roussel receives marketing approval for Allegra

Alliance signed for asthma disease management program

Potent 5-lipoxygenase inhibitors from Yakult Honsha

Cyclohexapeptides with multiple utilities reported by Hoechst

Serine protease inhibitors in Teijin's R&D pipeline

Angiotensin II antagonists disclosed by Tanabe Seiyaku

KRH-594: Wakunaga's angiotensin II antagonist

Renin inhibitors described by Ciba-Geigy

Eisai terminates E-4177 development

SmithKline Beecham and Meiji Seika to comarket levcromakalim

Status update of Recordati's lercanidipine HCl

Biovail's diltiazem covered under U.S. patent

UCB reports alpha-adrenergic ligands with cardiovascular activity

FDA clears Mylan's nicardipine HCl

Nitric oxide synthase inhibitors described by Hoechst

More nitric oxide synthase inhibitors from Japan Tobacco

RPR's enoxaparin reduces risk of DVT following hip replacement

Thrombin inhibitors inhelabo's pipeline

RO-11 demonstrates efficacy in phase III as DVT prevention agent

Piperazine fibrinogen antagonists from Thomae

Bicyclic fibrinogen antagonists described by SmithKline Beecham

Astra reports gastrin secretion inhibitors

Canadian researchers report GLP-2's potential as digestive disease treatment

FDA approves phaseI/II trial of VivoRx's BetaRx-P

Aldose reductase inhibitors disclosed by Nippon Zoki

Columbia seeks FDA approval of Crinone

Takeda seeks German approval for idebenone

Ortho reveals fibrinogen antagonists

Preliminary trial results demonstrate safety of Reticulose

Chronic bronchitis patients undergo Pseudostat phase II trials

FDA approves new formulation of Gensi Laboratories' etoposide

9-cis-retinoids as heart disease therapy described by American Cyanamid

Myco Pharmaceuticals to be called ChemGenics Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...